All Type of News
Domestic companies’ trouble in Brilinta’s substance patent
It was known although domestic pharmaceutical companies are competing over nullifying the patent of the AstraZeneca’s anticoagulant, ‘Brilinta,’ they are observed to have difficulties on the most important one, the su...
What has changed in 4 years after ‘Pharma Korea 2020’ announcement
The Korean pharmaceutical industry has met the 4-year anniversary of announcing the ‘Pharma Korea 2020’ vision on the 26th.
At the ‘2020 Vision and Roadmap Conference of Korea’s Pharmaceutical Industry’ jointly held ...
Multinational pharma companies’ entertainment expenses increased by 8% last year
It was observed major multinational pharmaceutical companies’ entertainment expenses was increased by more than 8% last year. They seem to show contrary to domestic pharmaceutical companies trying to cut entertainment...
KPMA pushes forward with survey on rebate-suspicious companies
The survey over rebate-suspicious companies, which has been postponed due to the government’s announcement of pharmaceutical industry’s promotional policy and certification of innovative pharmaceutical companies, is e...
What are impacts of SK and Hanmi’s ‘low-volume Xarelto generic’ approvals?
SK Chemicals and Hanmi Pharm which succeeded in developing the first generics of the novel oral anticoagulant(NOAC), Xarelto, acquired the low volume and entire volumes respectively.
Particularly, since the two compa...
“Mongolia is a country with large market to pioneer like its extensive grassland”
The Korea Pharmaceutical Manufacturers Association unveiled the President Kyung-ho Lee’s schedule as one of the economic delegation of the Presidential visit to Mongolia at an event called ‘Pharmaceutical Companies’ V...
MSD Korea launches 9-valent cervical cancer, Gardasil 9MSD Korea(CEO Avi Ben-Shoshan) announced a launch of its cervical cancer vaccine Gardasil 9(9-valent human papillomavirus vaccine). Gardasil 9 acquired domestic commercializatio...
|
Baraclude gives off its throne in 7 years, continued by Viread
No throne can last forever.
‘Baraclude,’ which has kept its top position for 7 consecutive years in the hepatitis B therapy market since 2011, has been weakened due to aggressive attacks of generics since October la...
MSD applies for ‘Zepatier’ approval, expecting competition among hepatitis C therapies
Another oral hepatitis C treatment seems to be introduced in Korea.
According to the industry concerned on the 26th, MSD turned in approval application of a new oral direct acting antiviral, ‘Zepatier(elbasvir+grazo...
Series of large decreases among pricey hepatitis C therapies
Prices of new hepatitis C therapies, which reached tens of thousands of wons with availability of full recovery, were largely reduced when entering the domestic market.
According to the recent ‘Insured Drug List and ...
